Circulation, Vol 84, 512-519, Copyright © 1991 by American Heart Association
C Vecchio, F Chiarella, G Lupi, P Bellotti and S Domenicucci
BACKGROUND. Streptokinase reduces the incidence of left ventricular
thrombosis after acute myocardial infarction. However, it is unknown
whether a similar effect can be obtained with different thrombolytic agents
and whether subcutaneous calcium heparin can have an additional efficacy.
METHODS AND RESULTS. To compare the effects of two different thrombolytic
agents combined or not with heparin on the incidence and features of left
ventricular thrombi and their related embolic events, we performed a
GISSI-2 ancillary echocardiographic study (the first echocardiogram
obtained within 48 hours of symptoms onset and the second before hospital
discharge) that enrolled 180 consecutive patients (mean age, 63 +/- 11
years, 142 men) with a first anterior acute myocardial infarction. Patients
were randomized into four groups of treatment: recombinant tissue-type
plasminogen activator (rt-PA) (n = 47), rt-PA plus heparin (n = 45),
streptokinase (n = 39), and streptokinase plus heparin (n = 49). Left
ventricular thrombosis was observed in 51 of 180 patients (28%). No
significant differences were found concerning the incidence of thrombi in
the four treatment groups. Mural shape of left ventricular thrombi was
found more frequently than the protruding shape (71% versus 29% at the
first examination, 64% versus 36% at the second), particularly in
heparin-treated patients (93% versus 7% at first examination, 70% versus
30% at the second). Only one embolic event (0.5%) occurred during the
hospitalization. CONCLUSIONS. We conclude that 1) the rate of left
ventricular thrombi does not differ in patients with acute myocardial
infarction treated either with streptokinase or rt-PA, 2) subcutaneous
heparin, when begun 12 hours after intravenous thrombolysis, does not
appear to further reduce the occurrence of thrombi but seems to influence
the shape of left ventricular thrombi, and 3) during the predischarge
period, embolic events are rare in patients treated by thrombolysis.
ARTICLES
Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis. A GISSI-2 connected study
Divisione di Cardiologia, EO Ospedale Galliera, Genova, Italy.
This article has been cited by other articles:
![]() |
G. G. Pellizzon, C. L. Grines, D. A. Cox, T. Stuckey, J. E. Tcheng, E. Garcia, G. Guagliumi, M. Turco, A. J. Lansky, J. J. Griffin, et al. Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1368 - 1374. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. O'Rourke, N. Dean, N. Akhtar, and A. Shuaib Current and future concepts in stroke prevention Can. Med. Assoc. J., March 30, 2004; 170(7): 1123 - 1133. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Cairns, P. Theroux, H. D. Lewis Jr., M. Ezekowitz, and T. W. Meade Antithrombotic Agents in Coronary Artery Disease Chest, January 1, 2001; 119 (2009): 228S - 252S. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1991 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |